metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)
es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)
versus trastuzumab
	trastuzumab emtansine vs. trastuzumab	1	none	inconclusive results for: deaths (OS)	statistically conclusive 50 % decrease in iDFS but the degree if certainty is unassessable	-
versus trastuzumab plus endocrine therapy
	trastuzumab emtansine vs. trastuzumab plus endocrine therapy	1	none	-	suggested 3.9-fold increase in pCR but the degree if certainty is unassessable	-
	trastuzumab emtasine plus endocrine therapy vs. trastuzumab plus endocrine therapy	1	none	-	suggested 4.0-fold increase in pCR but the degree if certainty is unassessable	-
la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib plus capecitabine
	trastuzumab emtansine vs. lapatinib plus capecitabine	1	none	inconclusive results for: DOR	statistically conclusive 32 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 25 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable statistically conclusive 35 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 73 % increase in objective responses (ORR) but the degree if certainty is unassessable	-
versus trastuzumab emtansine
	trastuzumab deruxtecan vs. trastuzumab emtansine	1	none	-	suggested 45 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 72 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-